losartan has been researched along with tacrolimus in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bravo, J; Campistol, JM; Capdevilla, L; del Castillo, D; Guirado, L; Martínez, JG; Pereira, P; Pérez, R | 1 |
| Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T | 1 |
| Bennett, T; Fallgren, B; Gardiner, SM; Kemp, PA; March, JE | 1 |
| Hotta, H; Ishikawa, S; Itoh, T; Kim, SJ; Kuno, A; Maeda, T; Miki, T; Miura, T; Satoh, T; Shimamoto, K; Tanno, M; Terashima, Y; Togashi, N; Yano, T | 1 |
| Ge, J; Gong, H; Li, L; Niu, Y; Sun, A; Wu, J; Zhou, N; Zou, Y | 1 |
| Günzel, C; Marx, N; Mischke, K; Noor-Ebad, F; Rana, OR; Saygili, E; Schauerte, P; Schwinger, RH | 1 |
| Abeyat, H; Behmanesh, MA; Poormoosavi, SM; Sangtarash, E | 1 |
2 review(s) available for losartan and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for losartan and tacrolimus
| Article | Year |
|---|---|
Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Female; Humans; Hypertension, Renal; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Losartan; Male; Postoperative Complications; Tacrolimus | 1998 |
12 other study(ies) available for losartan and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Body Weight; Calcineurin; Calcineurin Inhibitors; Cardiomegaly; Collagen Type III; Cyclosporine; Enzyme Inhibitors; Fibrosis; Heart; Immunosuppressive Agents; Losartan; Male; Mineralocorticoids; Myocardium; Nephrectomy; Organ Size; Rats; Rats, Inbred WKY; RNA, Messenger; Sodium Chloride, Dietary; Tacrolimus | 2002 |
Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cyclosporine; Drug Interactions; Heart Rate; Hemodynamics; Immunosuppressive Agents; Indans; Infusions, Intravenous; Losartan; Male; Phentolamine; Propranolol; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Renal Circulation; Sirolimus; Tacrolimus | 2004 |
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin, Leucine-2-Alanine; Erythropoietin; Immunosuppressive Agents; Ischemic Preconditioning, Myocardial; Janus Kinase 2; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred OLETF; Receptor, Angiotensin, Type 1; Receptors, Opioid, delta; Signal Transduction; Species Specificity; Tacrolimus; Tetrazoles; Up-Regulation; Valine; Valsartan | 2010 |
Mechanical stress-evoked but angiotensin II-independent activation of angiotensin II type 1 receptor induces cardiac hypertrophy through calcineurin pathway.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Calcineurin Inhibitors; Cardiomegaly; Chlorocebus aethiops; COS Cells; Losartan; Mice; Mice, Mutant Strains; Receptor, Angiotensin, Type 1; Stress, Mechanical; Tacrolimus | 2010 |
Irregular electrical activation of intrinsic cardiac adrenergic cells increases catecholamine-synthesizing enzymes.
Topics: Animals; Calcineurin Inhibitors; Catecholamines; Coculture Techniques; Cyclosporine; Dopamine beta-Hydroxylase; Electric Stimulation; Endothelin A Receptor Antagonists; Epinephrine; Losartan; Metoprolol; Myocardium; Myocytes, Cardiac; NFATC Transcription Factors; Peptides, Cyclic; Rats; Signal Transduction; Tacrolimus; Tyrosine 3-Monooxygenase | 2011 |
Evaluation of the Effect of Captopril and Losartan on Tacrolimus-induced Nephrotoxicity in Rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Urea Nitrogen; Captopril; Creatinine; Epithelium; Kidney Diseases; Kidney Tubules, Proximal; Losartan; Male; Peptidyl-Dipeptidase A; Rats; Renin-Angiotensin System; Tacrolimus | 2021 |